Abstracts tagged "Biomarkers"

Abstract Number: 2073 • ACR Convergence 2025
Cell-free DNA as a Potential Marker of Muscle Involvement and Treatment Response in Myositis
Sabína Oreská¹, Kristina Svobodová¹, Lucia Vernerová¹, Dana Dlouhá², Hana Wunsch¹, Karel Pavelka¹, Jiri Vencovsky³, Ladislav Šenolt⁴, Michal Vrablik⁵, Jaroslav Alois Hubáček² and Michal Tomcik¹, ¹Institute of Rheumatology and Department of Rheumatology, ¹st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Experimental Medicine Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, ³Institute of Rheumatology, Praha ⁸, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵³rd Department of Internal Medicine, General University Hospital and ¹st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are characterized by inflammatory muscle injury. Circulating cell-free DNA (cfDNA), including nuclear (cfnDNA) and mitochondrial (cfmtDNA) DNA, has been shown…
Abstract Number: 1811 • ACR Convergence 2025
Pharmacogenomic analysis of prediction of IL-1 Inhibitor treatment response in the CARRA First-line Options for Systemic Juvenile Idiopathic Arthritis Treatment (FROST) Study
Mariana Correia Marques¹, Michael Matt², Sophia Chou³, Peter Burbelo⁴, Zuoming Deng⁵, George Tomlinson⁶, Yukiko Kimura⁷, Grant Schulert² and Michael Ombrello⁸, ¹Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Rockville, MD, ⁴Adeno-Associated Virus Biology Section, National Institute of Dental and Craniofacial Research (NIDCR), Bethesda, ⁵Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁶University of Toronto, Toronto, ON, Canada, ⁷Hackensack Meridian School of Medicine, New York, NY, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), North Bethesda, MD
Background/Purpose: Interleukin (IL)-1 inhibitors are now regarded as the first line treatment option for systemic juvenile idiopathic arthritis (sJIA), however in up to half of…
Abstract Number: 1683 • ACR Convergence 2025
Serum APRIL Is Associated With B-Cell Activation Markers, Disease Activity, and Lymphoma Risk in Sjögren Disease (SD): Data From the prospective ASSESS Cohort
Pierre-Marie Duret¹, Pascal Schneider², Ludivine Robin³, Marine Vierling⁴, Nicolas Meyer⁵, Valerie Devauchelle⁶, Divi Cornec⁷, Alain SARAUX⁸, Jean Sibilia⁹, Raphaele Seror¹⁰, Yann Nguyen¹¹, Gaetane Nocturne¹², Laurent Mauvieux¹³, Laurent Miguet¹⁴, Xavier Mariette¹⁵ and Jacques-eric GOTTENBERG¹⁶, ¹Colmar General Hospital; Strasbourg University Hospital, Strasbourg, France, ²Université de Lausanne,Département de biochimie, Lausanne, Switzerland, ³Strasbourg University Hospital, Department of pathology, ⁴CNRS, Immunopathologie et Chimie Thérapeutique/Laboratory of Excellence Medalis, Institut de Biologie Moléculaire et Cellulaire (IBMC), Strasbourg, France Strasbourg, France;, Strasbourg, Alsace, France, ⁴Strasbourg University Hospital, Department of Public Health, GMRC, Strasbourg, France,, Strasbourg, Alsace, France, ⁵Strasbourg University Hospital, Department of Public Health, GMRC, Strasbourg, France, Strasbourg, Alsace, France, ⁶UBO, Brest, France, ⁷LBAI, UMR¹²²⁷, University of Brest, CHU Brest, Brest, France, Brest, Bretagne, France, ⁸CHU Brest, Brest, France, ⁹Rheumatology Department, National Center for Rare autoimmune disease RESO,Strasbourg University Hospital, Strasbourg, Alsace, France, ¹⁰Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR¹¹⁸⁴: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, ¹¹Department of Internal Medicine, Beaujon Hospital, AP-HP Nord, Université Paris Cité, Clichy, France, Clichy, France, ¹²University Paris Saclay, Le Kremlin Bicetre, Ile-de-France, France, ¹³Strasbourg University Hospital, Laboratory hematology, Strasbourg, France,CNRS, Immunopathologie et Chimie Thérapeutique/Laboratory of Excellence Medalis, Institut de Biologie Moléculaire et Cellulaire (IBMC), Strasbourg, France, Strasbourg, Alsace, France, ¹⁴Strasbourg University Hospital, Laboratory hematology, Strasbourg, France, CNRS, Immunopathologie et Chimie Thérapeutique/Laboratory of Excellence Medalis, Institut de Biologie Moléculaire et Cellulaire (IBMC), Strasbourg, France, Strasbourg, Alsace, France, ¹⁵Université Paris-Saclay, Le Kremlin Bicetre, France, ¹⁶Hautepierre Hospital, STRASBOURG, Alsace, France
Background/Purpose: Sjögren disease (SD) is a B cell driven systemic auto-immune disease, with a need for biomarkers to better assess disease activity, risk of lymphoma…
Abstract Number: 1442 • ACR Convergence 2025
Modulation of Soluble Biomarkers of Cartilage and Bone Turnover and Inflammation by Zasocitinib (TAK-279), an Oral, Allosteric, Highly Selective and Potent TYK2 Inhibitor, is Associated with Clinical Response in Patients with Active Psoriatic Arthritis
Amit Choudhury¹, Jie Cheng², Feng Hong¹, Sachin Kumar¹, Ayumu Sugiura³, Jay Tang¹, Banishree Saha¹, Vinayagam Arunachalam³, Ting Hong³, Elena Tomaselli Muensterman¹, Haakan Wennbo³, Paresh Thakker¹ and Iain McInnes⁴, ¹Takeda Development Center Americas, Inc.,, Cambridge, MA, ²Takeda Development Center Americas, Inc., Cambridge, MA, ³Takeda Development Center Americas, Inc, Cambridge, MA, ⁴University of Glasgow, Glasgow, United Kingdom
Background/Purpose: As a chronic inflammatory disease, PsA is marked by cartilage and bone turnover and articular inflammation. Accordingly, elevated levels of inflammation and bone metabolism…
Abstract Number: 1210 • ACR Convergence 2025
Artificial Intelligence-Based Capillaroscopy and Laboratory Biomarkers to Predict Disease Activity in Idiopathic Inflammatory Myopathies: Preliminary Data from the CapIAMI Cohort
Gema María Lledó Ibáñez¹, Jorge Álvarez-Troncoso², Borja del Carmelo Gracia Tello³, Sergio Prieto-Gonzalez⁴, Elena Martínez Robles⁵, Diana Cristina-Varela⁶, Sebastián Molina-Ríos⁷, Luis Sáez Comet⁸, Eiman Soliman⁹, Franklin Uguña¹⁰, Miguel Antonio Mesa¹¹, Miguel Martín Cascón¹², Tânia Santiago¹³, Grace-Jimena Santamaría-Peñaloza¹⁴, Tsvetoslav Georgiev¹⁵, Santiago Bernal-Macias¹⁶, Begoña Marí-Alfonso¹⁷, Jesus Ballano Rodríguez-Solís¹⁸, Sally Patricia Pino Hernández¹⁹, Jacek Olas²⁰, Juan Manuel Mosquera Angarita²¹, Elena García- Guijarro²², Isabel Perales Fraile²³, Mayka Freire Dapena²⁴, Iván Pérez de Pedro²⁵, Luis Adrián Viteri Noël²⁶ and Eduardo Ramos ibáñez²⁷, ¹Hospital Clínic de Barcelona, Barcelona, Spain, ²Hospital Universitario La Paz, Madrid, Madrid, Spain, ³Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ⁴Hospital Clinic, Barcelona, Catalonia, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶Unidad de Reumatología, Hospital General de Medellín, Medellín, Colombia, Medellín, Colombia, ⁷Hospital Universitario Nacional de Colombia, Bogotá, Colombia, Bogotá, Colombia, ⁸Hospital Universitario Miguel Servet, Zaragoza, Spain, ⁹Alexandria Faculty of Medicine, Alexandria, Egypt, ¹⁰Sociedad Ecuatoriana de Reumatologia, Quito, Ecuador, ¹¹Universidad Pontificia Bolivariana, Medellin, Colombia, ¹²Hospital General Universitario Morales Meseguer, Murcia, Spain, ¹³ULS de Coimbra, Coimbra, Portugal, ¹⁴Hospital Metropolitano, Quito, Ecuador, ¹⁵Hospital St. Marina, Varna, Varna, Bulgaria, ¹⁶Hospital Universitario San Ignacio, Bogotá, Colombia, ¹⁷Hospital Universitario Parc Taulí, Barcelona, Spain, ¹⁸Hospital Universitario del Henares, Alcalá de Henares, Madrid, Spain, ¹⁹Asoreuma, Care for Kids, Bogota, Distrito Capital de Bogota, Colombia, ²⁰MCRIiR, Szpital Specjalistyczny im. J. Dietla w Krakowie, Cracow, Poland, ²¹Hospital Sant Joan de Déu, Barcelona, Spain, ²²Hospital Universitario Infanta Cristina, Madrid, Spain, ²³Hospital Universitario Infanta Sofía, Madrid, Spain, ²⁴Hospital Clínico Universitario de Santiago de Compostela, La Coruña, Spain, ²⁵Hospital Regional Universitario de Málaga, Málaga, Spain, ²⁶Hospital Universitario Ramón y Cajal, Madrid, Spain, ²⁷Capillary.io, Zaragoza, Aragon, Spain
Background/Purpose: Nailfold videocapillaroscopy (NVC) is a valuable non-invasive tool for assessing microvascular damage in autoimmune diseases. However, its application in idiopathic inflammatory myopathies (IIM) remains…
Abstract Number: 0664 • ACR Convergence 2025
Pharmacodynamic Effects of Obinutuzumab on B cells and Serological Markers in Patients With Active Lupus Nephritis: Results From a Phase III Trial
Richard Furie¹, Ioannis Parodis², Rachel Jones³, Liz Lightstone⁴, Olivia Hwang⁵, Amelia Au-Yeung⁵, Imran Hassan⁶, Huiyan Mao⁶, William Pendergraft⁵, Jay Garg⁵, Harini Raghu⁵ and Brad Rovin⁷, ¹Division of Rheumatology, Northwell Health, Great Neck, NY, ²Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ³Renal Medicine, Cambridge University Hospitals, Cambridge, England, United Kingdom, ⁴Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, England, United Kingdom, ⁵Genentech, Inc., South San Francisco, CA, ⁶Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁷The Ohio State University, Columbus, OH
Background/Purpose: Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus, marked by kidney inflammation and damage. Obinutuzumab, a glycoengineered, type II CD20 antibody…
Abstract Number: 0861 • ACR Convergence 2025
Identification of Anti-HDGFL1 as a Novel Autoantibody in Seronegative Idiopathic Inflammatory Myopathies
Xueting Yuan¹, Menghua Cai², Lu Gao², Chen Yu³, Jia Shi⁴, Yinghui Li², jiuliang Zhao¹, Dong Xu⁵, Chaojun Hu¹, Mengtao Li⁶, Xiaofeng Zeng⁷, jianmin Zhang² and Qian Wang⁶, ¹Peking Union Medical College Hospital (CAMS), Beijing, China (People's Republic), ²Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, China (People's Republic), ³Peking Union Medical College Hospital, Dong Cheng Qu, Beijing, China (People's Republic), ⁴University of Washington, Seattle, WA, ⁵Peking Union Medical College Hospital, Dong Cheng District, China (People's Republic), ⁶Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ⁷Peking Union Medical College Hospital Department of Rheumatology and Clinical Immunology, Beijing, Beijing, China (People's Republic)
Background/Purpose: Myositis-specific autoantibodies (MSAs) play a crucial role in diagnosing and classifying idiopathic inflammatory myopathies (IIMs). However, approximately 30% of seronegative IIM patients may be…
Abstract Number: 0751 • ACR Convergence 2025
Impact of Treatment with Upadacitinib on Biomarkers Identified by Proteomics in Giant Cell Arteritis
Lisa Christ¹, Shalina Taylor², Yilin Xu², Rhiya Sharma², Thierry Sornasse², Yingtao Bi², Heath Guay², Arathi Setty³, Ana Romero⁴, Peter Merkel⁵, Eugenio de Miguel⁶, Christian Dejaco⁷ and Cornelia Weyand⁸, ¹Department of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Bern, Switzerland, ²AbbVie Inc, North Chicago, ³AbbVie Inc, North Chicago, IL, ⁴AbbVie, Barcelona, Spain, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Hospital Universitario La Paz, Madrid, Spain, ⁷Medical University of Graz, Department of Rheumatology, Graz, Austria; Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, ⁸Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester
Background/Purpose: Interleukin-6 (IL-6) and interferon-gamma (IFNγ) have been identified as key drivers in the pathogenesis of giant cell arteritis (GCA), that promote disease progression. The…
Abstract Number: 0341 • ACR Convergence 2025
Romosozumab in patients with Osteoporosis: Safety and Efficacy analysis in Clinical Practice
Daniel Ramos Castro¹, SAMUEL LEAL², ELENA GRAU GARCIA³, Pablo Muñoz-Martínez⁴, Laura Mas Sanchez⁵, Alba Maria Torrat Noves⁶, Belen Villanueva Manes⁷, Iago Alcántara Álvarez⁸, Andres perez Hurtado⁹, Miguel Simeo Vinaixa⁹ and José Andrés Román Ivorra¹⁰, ¹Hospital Universitari i Politecnic La Fe, Valencia, Spain, ²Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ³HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁴Hospital Universitario y Politécnico La Fe, Sagunto, Spain, ⁵Hospital Universitari i Politecnic La Fe, València, Spain, ⁶Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain, ⁷Hospital La Fe, València, Spain, ⁸Hospital Universitari i Politénic La Fe, València, Spain, ⁹Rheumatology Department. HUP La Fe, Valencia, Spain, ¹⁰Hospital Universitari i Politècnic La Fe, Valencia, Spain
Background/Purpose: Osteoporosis is the most common bone metabolism disorder in developed countries. It increases the risk of fragility fractures, impairing quality of life, increasing disability,…
Abstract Number: 0052 • ACR Convergence 2025
Profiling of MT-3534, a Humanized Monoclonal Antibody Targeting Peptidylarginine Deiminase 4, as a Candidate Drug for the Treatment of RA
Hisae Niki¹, Akitoshi Nishizawa², Yuuichi Ono¹, Makoto Yamazaki¹, Satoshi Takanashi³, Keiko Yoshimoto⁴, Mitsuhiro Akiyama³, Tsutomu Takeuchi⁵ and Yuko Kaneko⁴, ¹Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan, ²Mitsubishi Tanabe Pharma Corporation, Fujisawa, Kanagawa, Japan, ³Keio University School of Medicine, Tokyo, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ⁵Saitama Medical University and Keio University, Tokyo, Japan
Background/Purpose: Although the management of rheumatoid arthritis (RA) has been remarkably improved, there are still patients who have not responded to existing targeted drugs that…
Abstract Number: 2511 • ACR Convergence 2025
The SHIPE index: A tertile-based approach to predict end-stage kidney disease in ANCA-associated vasculitis
HYUNSUE DO¹, Lucy Eunju Lee², Jang Woo Ha³, Jason Jungsik Song⁴, Yong-Beom Park⁵ and Sang-Won Lee⁶, ¹Kangwon national university hospital, Seoul, South Korea, ²Yonsei University, Seoul, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Republic of Korea, ⁴Yonsei University College of Medicine, Seoul, Republic of Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea, ⁶Yonsei university college of medicine, Seoul, South Korea
Background/Purpose: This study aimed to develop a simple, robust, and ethnoregion-specific index for predicting progression to end-stage kidney disease (ESKD) in Korean patients with antineutrophil…
Abstract Number: 2277 • ACR Convergence 2025
Immunophenotyping of peripheral blood mononuclear cells reveals potential cellular biomarkers of disease in rheumatoid arthritis
John Bui¹, Jason Dubovsky², Jennifer Abrams³, Sara Charmsaz⁴, Michelle Blake¹, Joshua Beilke⁴, Anne-Renee van der Vuurst de Vries¹, Joseph Arron⁵, Jonathan Graf⁶ and Jeffrey Bluestone⁷, ¹Sonoma Biotherapeutics, Seattle, WA, ²Sonoma Biotherapeutics, South San Francisco, ³Sonomabio, San Francisco, CA, ⁴Sonoma Biotherapeutics, Seattle, ⁵Sonoma Biotherapeutics, San Francisco, CA, ⁶UCSF, San Francisco, CA, ⁷Sonoma Biotherapeutics, South San Francisco, CA
Background/Purpose: Emerging cell-based therapies for rheumatoid arthritis (RA) target the underlying immunologic activity of disease. Objective biomarkers to-date are downstream sequelae of RA immunologic drivers.…
Abstract Number: 2062 • ACR Convergence 2025
Immune Cell Signatures Associated with Disease Activity in Dermatomyositis Across Autoantibody Subtypes
Jeffrey Sagun¹, Melissa Leeolou¹, Nicholas Geraci², Andrew Bender³, Fatima Strand², David Fiorentino¹ and Kavita Sarin¹, ¹Department of Dermatology, Stanford University Medical Center, Stanford, CA, ²EMD Serono, Billerica, MA, ³AbbVie, Worcester, MA
Background/Purpose: Dermatomyositis (DM) is a heterogeneous multisystem autoimmune disease characterized by inflammation of the skin, muscle, and lung. Identifying the immune cells that drive disease…
Abstract Number: 1809 • ACR Convergence 2025
Mass Spectrometry-Based N-Terminomics Uncovers Proteolytic Signatures and Pathways in Juvenile Idiopathic Arthritis Synovial Fluid
Andrew Zeft¹, Sirada Panupattanapong², Laura Nedorezov³, Sumit Bhutada³ and Suneel Apte³, ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic Foundation, Cleveland, OH, ³Cleveland Clinic, Cleveland
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic disease marked by persistent synovial inflammation, often leading to structural joint damage. While numerous proteases produced by…
Abstract Number: 1680 • ACR Convergence 2025
Major salivary gland ultrasonographic features of lymphoma and high lymphoproliferative risk lesions in Sjögren’s Disease: a systematic review
Alen Zabotti¹, Valeria Manfrè¹, Maria Teresa Rizzo¹, Alessia Nano¹, Garifallia Sakellariou² and Luca Quartuccio¹, ¹Division of Rheumatology, Department of Medicine (DMED), Academic Hospital "Santa Maria della Misericordia", ASUFC, University of Udine, Udine, Italy, Udine, Italy, ²Department of Internal Medicine and Therapeutics, Università Di Pavia, Pavia, Italy; Istituti Clinici Scientifici Maugeri IRCCS Pavia, Pavia, Italy
Background/Purpose: Sjögren's disease (SjD) is burdened by significant lymphoproliferative risk. Up to date there is no established consensus on the salivary gland ultrasonographic (SGUS) features…

« Previous Page
1
…
4
5
6
7
8
…
109
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].